Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

The hefty price tag for GLP-1s – glucagon-like peptide-1 agonists – puts these blockbuster ... For patients paying out of pocket, these drugs are not cheap. In the U.S., a month’s worth ...

The category is expected to scale to $8.7 billion by 2027. The market for GLP-1 agonist drugs also continues to grow and is expected to exceed $100 billion by 2030. NBJ's report aims to educate ...

unveil a special report highlighting how dietary supplements are complementary to the booming GLP-1 agonist drugs market. The report titled Supplements in the Ozempic Age, outlines the current ...